← Back to Search

Contrast Solution

Hepatitis C for Liver scarring

Phase 4
Waitlist Available
Led By Krishna Juluru, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
Pivotal Trial
Drug Has Already Been Approved
No Placebo-Only Group

Summary

When someone has hepatitis C or some other condition that causes liver injury, he or she can develop a condition called liver fibrosis that over time, can cause the liver to stop working normally. Currently, the best way to determine the degree of fibrosis is to do a liver biopsy. The investigators hope to show that measuring the degree of liver fibrosis using an MRI with gadoxetate disodium is as good as or better than obtaining this information by performing a liver biopsy. Gadoxetate disodium is a contrast solution given through the veins that is considered safe, is approved for use by the Food and Drug Administration, and is already routinely given to patients with various forms of liver disease, including fibrosis.

Eligible Conditions
  • Liver scarring

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The transfer constant, Ktrans, between intravascular and interstitial compartments.

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Hepatitis CExperimental Treatment1 Intervention
Subjects with hepatitis C. Subjects will obtain both MRI of liver and limited CT of liver.
Group II: Normal liver functionActive Control1 Intervention
Control group. Subjects will obtain MRI of liver.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MRI of liver
2017
N/A
~20

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,083 Previous Clinical Trials
1,138,667 Total Patients Enrolled
Krishna Juluru, MDPrincipal InvestigatorWeill Medical College of Cornell University
~3 spots leftby Nov 2025